Manuela Campiglio

8.2k total citations · 1 hit paper
60 papers, 6.7k citations indexed

About

Manuela Campiglio is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Manuela Campiglio has authored 60 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 30 papers in Molecular Biology and 30 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Manuela Campiglio's work include HER2/EGFR in Cancer Research (35 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and Cell Adhesion Molecules Research (8 papers). Manuela Campiglio is often cited by papers focused on HER2/EGFR in Cancer Research (35 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and Cell Adhesion Molecules Research (8 papers). Manuela Campiglio collaborates with scholars based in Italy, United States and Germany. Manuela Campiglio's co-authors include Sylvie Ménard, Elda Tagliabue, Serenella M. Pupa, Carlo M. Croce, Marilena V. Iorio, Angelo Veronese, Silvia Sabbioni, Manuela Ferracin, Chang‐Gong Liu and Italo Nenci and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Molecular and Cellular Biology.

In The Last Decade

Manuela Campiglio

60 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNA Gene Expression Deregulation in Human Breast Cancer

2005 3.3k citations Marilena V. Iorio, Manuela Ferracin et al. Cancer Research profile →

Peers

Countries citing papers authored by Manuela Campiglio

Since Specialization

Citations

This map shows the geographic impact of Manuela Campiglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuela Campiglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuela Campiglio more than expected).

Fields of papers citing papers by Manuela Campiglio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuela Campiglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuela Campiglio. The network helps show where Manuela Campiglio may publish in the future.

Co-authorship network of co-authors of Manuela Campiglio

This figure shows the co-authorship network connecting the top 25 collaborators of Manuela Campiglio. A scholar is included among the top collaborators of Manuela Campiglio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuela Campiglio. Manuela Campiglio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment 2020 ·Cells ·Ilona Rybińska, Marco Sandri, Francesca Bianchi, Rosaria Orlandi, Loris De Cecco, Patrizia Gasparini, Manuela Campiglio, Biagio Paolini, Lucia Sfondrini, Elda Tagliabue, Tiziana Triulzi	3
2	Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor 2016 ·OncoImmunology ·Valentino Le Noci, Michele Sommariva, Monica Tortoreto, Nadia Zaffaroni, Manuela Campiglio, Elda Tagliabue, Andrea Balsari, Lucia Sfondrini	30
3	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens 2014 ·Cancers ·Antonia Martinetti, Rosalba Miceli, Elisa Sottotetti, Maria Di Bartolomeo, Filippo de Braud, Arpine Gevorgyan, Katia Dotti, Emilio Bajetta, Manuela Campiglio, Francesca Bianchi, Giacomo Bregni, Filippo Pietrantonio	16
4	â€œOmicsâ€ and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas 2014 ·Frontiers in Oncology ·Elda Tagliabue, Manuela Campiglio	2
5	Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study 2013 ·Breast Cancer Research and Treatment ·Manuela Campiglio, Rosaria Bufalino, (unknown), Elisa Ferri, Patrizia Casalini, Vincenzo Adamo, Alessandra Fabi, (unknown), Ferdinando Riccardi, Eva M. Martín del Valle, Vieri Scotti, (unknown), Dario Giuffrida, Emiliana Tarenzi, Alessandra Bologna, Giorgio Mustacchi, Francesca Bianchi, Andrea Balsari, Sylvie Ménard, Elda Tagliabue	20
6	Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy 2011 ·Journal of Cellular Physiology ·Valentina Ciravolo, Veronica Huber, Gaia C. Ghedini, Elisabetta Venturelli, Francesca Bianchi, Manuela Campiglio, Daniele Morelli, Antonello Villa, Pamela Della Mina, Sylvie Ménard, Paola Filipazzi, Licia Rivoltini, Elda Tagliabue, Serenella M. Pupa	417
7	HER2 as a target for breast cancer therapy 2010 ·Expert Opinion on Biological Therapy ·Elda Tagliabue, Andrea Balsari, Manuela Campiglio, Serenella M. Pupa	72
8	Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN 2009 ·Journal of Immunotherapy ·Michelandrea De Cesare, Lucia Sfondrini, Manuela Campiglio, Michele Sommariva, Francesca Bianchi, Paola Perego, Nico van Rooijen, Rosanna Supino, Cristiano Rumio, Franco Zunino, Graziella Pratesi, Elda Tagliabue, Andrea Balsari	19
9	Fhit Expression Protects Against HER2-Driven Breast tumor Development: Unraveling the Molecular Interconnections 2007 ·Cell Cycle ·Francesca Bianchi, Elda Tagliabue, Sylvie Ménard, Manuela Campiglio	16
10	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib 2006 ·Journal of Cellular Physiology ·Nicola Normanno, Antonella De Luca, Monica R. Maiello, Manuela Campiglio, Maria Napolitano, Mario Mancino, (unknown), Giuseppe Viglietto, Sylvie Ménard	119
11	MicroRNA Gene Expression Deregulation in Human Breast Cancer breakdown → 2005 ·Cancer Research ·Marilena V. Iorio, Manuela Ferracin, Chang‐Gong Liu, Angelo Veronese, Riccardo Spizzo, Silvia Sabbioni, Eros Magri, Massimo Pedriali, Muller Fabbri, Manuela Campiglio, Sylvie Ménard, Juan Palazzo, Anne Rosenberg, Piero Musiani, Stefano Volinia, Italo Nenci, George A. Calin, Patrizia Querzoli, Massimo Negrini, Carlo M. Croce	3320
12	Role of HER2 in wound-induced breast carcinoma proliferation 2003 ·The Lancet ·Elda Tagliabue, Roberto Agresti, Maria Luisa Carcangiu, Cristina Ghirelli, Daniele Morelli, Manuela Campiglio, Maritza Martel, Riccardo Giovanazzi, Marco Greco, Andrea Balsari, Sylvie Ménard	128
13	Biologic and therapeutic role of HER2 in cancer 2003 ·Oncogene ·Sylvie Ménard, Serenella M. Pupa, Manuela Campiglio, Elda Tagliabue	350
14	The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2 2003 ·Cellular Signalling ·Parham Minoo, Naila Chughtai, Manuela Campiglio, Matthias Stein-Gerlach, Jean-Jacques Lebrun, Axel Ullrich, Suhad Ali	9
15	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. 2002 ·PubMed ·Sylvie Ménard, Andrea Balsari, Patrizia Casalini, Elda Tagliabue, Manuela Campiglio, Rosaria Bufalino, Natale Cascinelli	73
16	HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer 2001 ·Annals of Oncology ·Sylvie Ménard, Patrizia Casalini, Manuela Campiglio, Serenella M. Pupa, Roberto Agresti, Elda Tagliabue	109
17	FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. 1999 ·PubMed ·Manuela Campiglio, Yuri Pekarsky, Sylvie Ménard, Elda Tagliabue, Silvana Pilotti, Carlo M. Croce	92
18	The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control 1999 ·Proceedings of the National Academy of Sciences ·Laura Sard, Paola Accornero, Silvana Tornielli, Domenico Delia, Giuseppe Bunone, Manuela Campiglio, Mario P. Colombo, (unknown), Carlo M. Croce, Marco A. Pierotti, Gabriella Sozzi	188
19	Overexpression of p185 is not related to erbB2 amplification in ovarian cancer 1993 ·Annals of Oncology ·(unknown), (unknown), Elda Tagliabue, Manuela Campiglio, Sylvie Ménard, (unknown), Valeria Lucchini, N. Colombo, Costantino Mangioni, L. Redaelli, (unknown)	6
20	Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency 1993 ·Cancer Immunology Immunotherapy ·Srinivas Uppugunduri, Elda Tagliabue, Manuela Campiglio, Sylvie Ménard, M. I. Colnaghi	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact